FDA Allows Phase IIb Long COVID Study to Treat Patients Suffering from Long-COVID

Pulthera, LLC has received notice from the US FDA Investigational New Drug that it can proceed with “A Phase IIb, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravenous Allogenic Bone Marrow-derived MSCs in Subjects with Dyspnea Associated with Post-acute Sequelae of SARS-CoV-2 Infection.”